

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement contains forward-looking statements that involve risks and uncertainties. All statements other than statements of historical fact are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, some of which are beyond the Company's control, that may cause the actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.



邁博藥業

Mabpharm Limited
迈博药业有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2181)

**INTERIM RESULTS ANNOUNCEMENT
FOR THE SIX MONTHS ENDED JUNE 30, 2022**

The Board of Mabpharm Limited is pleased to announce the unaudited consolidated financial results of the Company and its subsidiaries for the six months ended June 30, 2022, together with the comparative figures for the six months ended June 30, 2021.

FINANCIAL HIGHLIGHTS

	For the six months ended June 30,		
	2022	2021	Change
	RMB'000	RMB'000	(%)
	(unaudited)	(unaudited)	
Revenue	28,847	81,246	(64.5)
Cost of sales	(11,054)	(16,769)	(34.1)
Gross profit	17,793	64,477	(72.4)
Other income	12,450	3,558	249.9
Other gains and losses	(2,862)	(4,719)	(39.4)
Selling and distribution expenses	(15,264)	–	N/A
Research and development expenses	(77,990)	(163,455)	(52.3)
Administrative expenses	(47,832)	(43,755)	9.3
Finance costs	(3,104)	(1,267)	145.0
Loss before tax	(116,809)	(145,161)	(19.5)
Income tax expense	–	–	N/A
Loss and total comprehensive expense for the period	(116,809)	(145,161)	(19.5)
Attributable to:			
Owners of the Company	(116,809)	(145,161)	(19.5)
Loss per share attributable to ordinary equity holders of the Company			
– Basic	RMB(0.03)	RMB(0.04)	
– Diluted	RMB(0.03)	RMB(0.04)	

	At June 30, 2022 RMB'000 (unaudited)	At December 31, 2021 RMB'000 (audited)	Change (%)
Non-current assets	713,775	652,132	9.5
Current assets	224,229	247,770	(9.5)
Current liabilities	223,021	235,004	(5.1)
Net current assets	1,208	12,766	(90.5)
Non-current liabilities	223,855	62,917	255.8
Net assets	491,128	601,981	(18.4)

CORPORATE PROFILE

We are a leading biopharmaceutical company in China, focusing on the research, development and commercialization of new drugs and biosimilar for cancers and autoimmune diseases. We strive to bring to the market high quality and affordable innovative biologics through our efficient research and development (“R&D”) system and low-cost pharmaceutical production capabilities, and develop differentiated therapeutic products by fully utilizing our extensive R&D experience. Our drug pipeline currently consists of 10 monoclonal antibody drugs and 1 strong antibody drug, 3 of which are our core products:

- **CMAB008 類停® (infliximab)**: was approved for marketing by the National Medical Products Administration of the People’s Republic of China (“NMPA”) in July 2021 (Guo Yao Zhun Zi S20210025) for the treatment of 1) ulcerative colitis in adults; 2) ankylosing spondylitis; 3) rheumatoid arthritis; 4) Crohn’s disease in adults and pediatric patients aged above 6 years old; 5) fistula Crohn’s disease; and 6) psoriasis. The antibody drug production base of Taizhou Mabtech Pharmaceutical Limited (泰州邁博太科藥業有限公司) under the Company in China Medical City, Taizhou, Jiangsu Province also successfully passed the GMP compliance inspection for CMAB008 by Jiangsu Provincial Drug Administration. According to the regulations of China’s basic medical insurance program (the “**Medical Insurance**”), CMAB008 類停® has also been automatically included in the Medical Insurance, and has obtained the Medical Insurance registration code from the National Healthcare Security Administration (the “**Healthcare Security Administration**”).

CMAB008 類停[®] is approved for the treatment of six indications which have huge long-term unmet market demand (with more than 10 million patients in the PRC which is still growing). We have established an online procurement platform covering 30 provinces within the PRC and included CMAB008 類停[®] in provincial medical insurance system, and completed channel distribution and product delivery for 30 provinces. During the Reporting Period, Taizhou Mabtech Pharmaceutical Limited* (泰州邁博太科藥業有限公司) (“**Taizhou Pharmaceutical**”), an indirect wholly-owned subsidiary of the Company, entered into an exclusive promotion service agreement with Kexing Biopharm Co., Ltd.* (科興生物製藥股份有限公司) (“**Kexing Biopharm**”), a company listed on the Science and Technology Innovation Board of Shanghai Stock Exchange (stock code: 688136), pursuant to which Taizhou Pharmaceutical granted an exclusive licence to promote CMAB008 類停[®] in mainland China (excluding Hong Kong, Macau and Taiwan regions) to Kexing Biopharm. Taizhou Pharmaceutical will receive partnership milestone payments and commercial milestone payments for this exclusive promotion license, and is expected to generate substantial revenue from ongoing sales in the future. For details of the above transaction, please refer to the announcement of the Company dated March 31, 2022. With high quality innovative drugs as the foundation, Mabpharm will provide innovative antibody drugs to patients in the PRC by offering more economical and affordable drug supply solutions and fully participating in China’s national healthcare system reform initiatives. The Company has also initiated cooperation with partners who have accumulated abundant overseas market resources over a long period of time to rapidly expand to overseas markets. At present, the Company has launched registration and market exploration in more than 30 countries and/or regions.

- **CMAB007 (omalizumab)**: completed phase III clinical trials for the indication of asthma and new drug application data collation. The new drug marketing application for CMAB007 has been submitted to the NMPA in October 2021. It has successfully passed site inspection by the NMPA, and is expected to be approved for commercialisation in the first quarter of 2023. We expect that upon commercialisation, CMAB007 will be the first home-made omalizumab launched in the domestic market. The Company has been seeking for cooperation with China’s leading drug manufacturers for the sale of CMAB007, aiming to achieve rapid increase in the sales volume of CMAB007. Given that similar drugs have been approved overseas for urticaria and allergic rhinitis indications and are developing to address food allergy indications, we will expedite the clinical and registration work of CMAB007 for these indications to capture the huge allergic disease market demand in China.
- **CMAB009 (cetuximab)**: currently under phase III clinical trials for colorectal cancer, completed case recruitment and finalising NDA data organisation, analysis and collection. CMAB009 uses the Chinese hamster ovary cell (“**CHO**”) expression system, which enjoys significant advantages in safety compared to existing marketed cetuximab products for treating metastatic colorectal cancer. CMAB009 is expected to file the new drug marketing application with the NMPA in the fourth quarter of 2022.
- **CMAB807 (denosumab)**: currently under phase III clinical trials for osteoporosis, completed case recruitment and is under data compilation for NDA application. The clinical trial application for treatment of tumor bone metastasis (CMAB807X) has been approved by NMPA in January 2022 (Clinical trial approval notice number: 2022LP00032).

Among our other drug candidates, our newly developed “strong antibody” drug CMAB017 has obtained approval from the NMPA for clinical trial for the treatment of advanced solid tumors, including but not limited to colorectal cancer, head and neck squamous cell carcinomas and esophageal squamous cell carcinoma. Compared with marketed EGFR anti-body drugs, CMAB017 has better efficacy and safety. In addition, we have commenced phase I clinical trials for CMAB819 (nivolumab). CMAB015 (secukinumab), a biosimilar developed by us, has been approved for and is initiating clinical trials, which boasts remarkable efficacy advantages in the treatment of autoimmune diseases such as psoriasis, and has become one of the most rapidly growing biological agents in the treatment of psoriasis in China. We have also developed CMAB022 (usnumab), a biosimilar, which promises sound market prospect for the treatment of psoriasis, ankylosing spondylitis and Crohn’s disease.

We have strong in-house capabilities in pharmaceutical research, manufacturing and pre-clinical and clinical development. We intend to promote the commercialisation of drugs developed by us through approaches including sales, license and cooperation, as well as establishment of an in-house sales team, so as to capitalise on the strong sales resources and experience of our business partners accumulated throughout the years, and meanwhile build up and enhance our own distinctive and efficient sales system with a focus on specific indications. We focus on the R&D of monoclonal antibodies. Our core R&D team members have more than 19 years of experience in this area, and have led three major projects under the “863” Program, among other national-level scientific research projects. In addition, one of our core R&D team members is also a member of the 11th Session of the Chinese Pharmacopoeia Commission.

We have completed the construction of three new production lines in Taizhou in 2021, increasing our total cell reactor scale to 18,000 liters. The construction of plants in our new R&D and industrial base in Taizhou has also been completed, and the Company’s large-scale GMP production line in construction has been under installation and commissioning, which is expected to be put into operation by the end of 2022 and will bring the aggregate scale of our cell reactor to over 40,000 liters. The solid equipment, technology and quality foundation we have in the field of antibody drug preparation will enable us to possess an excellent competitive advantage in future medical insurance and centralized procurement negotiations. Leveraging the competitive advantages in the R&D and mass production capacity in anti-body drugs in the PRC, we also proactively engaged in CDMO business without compromising our independent product R&D, and secured desirable results.

We believe that we are well positioned to seize China’s substantial market opportunities, in particular those resulting from China’s recent healthcare regulatory reforms, including new medical insurance measures. The primary focus of our R&D – monoclonal antibody drugs targeting cancers and autoimmune diseases – has substantial untapped clinical demand in China.

Further, during the rapid growth of the pharmaceutical market in China, the central procurement under the medical insurance that may be extended to cover biological drugs in the future and the increased effort in national negotiations on medical insurance will restructure the pharmaceutical market in China to a large extent. We will actively participate in the national medical reform with our advantages in terms of advanced technology, quality and cost, as well as aggressive and flexible product cooperation model, and capture the opportunities presented during the policy reform so as to capture the huge unmet market demand in China. We have also initiated our global market expansion and accelerated the registration and launching of our drugs in the international market.

MANAGEMENT DISCUSSION AND ANALYSIS

Business Review

Research and development of our drug candidates

Set out below is an overview of our drug candidates and their R&D status as of June 30, 2022:

Field	Target	Indication	Drug candidate code	Classification	Pre-clinical	Phase I	Phase II or Phase II/III	Phase III	Expected time to reach the next regulatory milestone	Anticipated completion of regulatory review	Commercial rights	Competitive marketed drugs
Autoimmune Disease	TNF α	Rheumatoid Arthritis Ulcerative colitis in adults Ankylosing spondylitis Crohn's disease in adults and paediatric patients aged above 6 years old Fistula Crohn's disease Psoriasis	CMAB008 (INN name: Infliximab)	New Drug/ Core Product					Not applicable	Approved for marketing in July 2021	PRC and overseas (excluding Japan, North America and Europe)	Remicade®, Humira®, Embrel®, Simponi®, Yisopri® and Abianuo®
Respiratory Disease	IgE	Asthma	CMAB007 (INN name: Omalizumab)	New Drug/Core Product					New drug marketing application submitted in October 2021	Quarter 1, 2023	PRC and overseas (excluding Japan, North America and Europe)	Xolair®
Cancer	EGFR	Colorectal cancer	CMAB009 (INN name: Cetuximab)	New Drug/Core Product					Pending new drug marketing application submission (Quarter 4, 2022)	Quarter 1, 2024	PRC and overseas (excluding Japan, North America and Europe)	Erbixu®
Bone-related diseases	RANKL	Osteoporosis	CMAB807 (INN name: Denosumab)	Biosimilar					Pending new drug marketing application submission (Quarter 3, 2023)	Quarter 4, 2024	Global	Prolia®
		Tumor bone metastasis	CMAB807X (INN name: Denosumab)	Biosimilar					Phase III (Quarter 4, 2023)	Quarter 4, 2027	Global	XGEVA®

Field	Target	Indication	Drug candidate code	Classification	Pre-clinical	Phase I	Phase II or Phase II/III	Phase III	Expected time to reach the next regulatory milestone	Anticipated completion of regulatory review	Commercial rights	Competitive marketed drugs
Cancer	PD1	Non-small cell lung cancer, hepatocellular carcinoma and squamous cell carcinoma of the head and neck	CMAB819 (INN name: Nivolumab)	Biosimilar					Phase III (Quarter 2, 2023)	Quarter 4, 2027	Global	Opdivo®, Keytruda®, Tyvyt®, JS001
Cancer	HER2	Breast cancer	CMAB810 (INN name: Pertuzumab)	Biosimilar					Phase III (Quarter 2, 2025)	Quarter 3, 2029	Global	Perjeta®
Cancer/Autoimmune Disease	IL-1 β	Periodic Fever Syndromes/ Systemic Juvenile Idiopathic Arthritis/Lung cancer	CMAB816 (INN name: Canakinumab)	Biosimilar					Phase III (Quarter 2, 2025)	Quarter 3, 2029	Global	Ilaris®
Cancer	EGFR	KRAS wild-type colorectal cancer	CMAB017	Innovative drug					Phase III (Quarter 4, 2024)	Quarter 4, 2028	Global	Vectibix®
Autoimmune Disease	IL-17A	Psoriasis and ankylosing spondylitis	CMAB015 (INN name: Secukinumab)	Biosimilar					Phase III (Quarter 2, 2023)	Quarter 4, 2025	Global	Cosenty®
Allergy, Inflammatory Disease	IL-5	Asthma and eosinophilic granulomatous polyangitis	CMAB018 (INN name: Mepolizumab)	Biosimilar					Phase III (Quarter 4, 2024)	Quarter 4, 2027	Global	Nucala®
Inflammatory Diseases	IL-12 & IL-23	Moderate to severe plaque psoriasis, psoriatic arthritis, active ankylosing spondylitis, active non-radiographic axial spondyloarthritis	CMAB022 (INN name: Ustekinumab)	Biosimilar					Phase III (Quarter 3, 2024)	Quarter 3, 2027	Global	Stelara®

Cautionary Statement required by Rule 18A.08(3) of the Listing Rules: We may not be able to ultimately develop and market our drug candidates (including Core Products) successfully.

Core Products

類停[®] – CMAB008 (infliximab)

CMAB008 (infliximab), trade name: 類停[®], is a recombinant anti-TNF-alpha chimeric monoclonal antibody that was approved by the NMPA (Guo Yao Zhun Zi S20210025) on July 12, 2021 for the treatment of:

- (i) ulcerative colitis in adults;
- (ii) ankylosing spondylitis;
- (iii) rheumatoid arthritis;
- (iv) Crohn's disease in adults and pediatric patients aged above 6 years old;
- (v) fistula Crohn's disease; and
- (vi) psoriasis.

CMAB008 類停[®] is the first China-made infliximab approved for marketing, which is a monoclonal antibody biosimilar independently developed by the Company and one of the core products of the Company. CMAB008 類停[®] uses the CHO expression system, and is a monoclonal antibody targeting TNF α (tumor necrosis factor α) that specifically merges with TNF α and blocks the inflammatory cascade response caused by TNF α . The researches we have completed have shown that, compared to other anti-TNF α drugs on the market, CMAB008 類停[®] (infliximab for injection) has a stronger affinity for TNF α and a stronger glycosylation character, with rapid onset of effect, long-lasting efficacy, long dosing intervals and no hypersensitivity reactions. The results of our completed researches including, clinical trials, non-clinical comparative studies and pharmacological comparisons of CMAB008 類停[®] have also shown that CMAB008 類停[®] is identical to the original infliximab in terms of efficacy, safety, pharmacological profile and quality.

CMAB008 類停[®] is the first infliximab launched in the domestic market following “Remicade”, the original drug imported and sold by Xi'an Janssen. CMAB008 類停[®] is approved for the treatment of six indications which have huge long-term unmet market demand with more than 10 million patients in the PRC which is still growing. During the past two and a half years, following the inclusion in the medical insurance system and shift in habit towards adopting biological agents, the overall market share of infliximab witnessed a rapid increase, especially in the field of IBD diseases, for which infliximab has become the key biological agent for treatment due to its rapid onset of effect and obvious curative effect.

During the Reporting Period, Taizhou Pharmaceutical entered into an exclusive promotion service agreement with Kexing Biopharm, pursuant to which Taizhou Pharmaceutical granted an exclusive licence to promote CMAB008 類停® in mainland China (excluding Hong Kong, Macau and Taiwan regions) to Kexing Biopharm. Taizhou Pharmaceutical will receive partnership milestone payments and commercial milestone payments for this exclusive promotion license, and is expected to generate substantial revenue from ongoing sales in the future. For details of the above transaction, please refer to the announcement of the Company dated March 31, 2022.

CMAB007 (omalizumab)

CMAB007 (omalizumab), a recombinant humanized anti-IgE monoclonal antibody, is our new drug candidate for treatment of asthma patients who remain inadequately controlled despite med/high dose of ICS plus LABA. We believe that, once approved by the NMPA for marketing, it will be the first mAb asthma therapy developed by a local Chinese company marketed in China. CMAB007 combines with free IgE to form an anti-IgE complex that inhibits the high affinity IgE receptor and thereby prevents the allergic response. The safety and efficacy of CMAB007 have been confirmed by the results of four clinical trials of a total of 824 subjects who have been administered CMAB007, which were the largest clinical trials of mAb treating asthma in China. Based on our clinical trial results, CMAB007 can improve asthma patients' conditions with lower-dose inhaled corticosteroids and reduce the incidence of acute asthma attacks.

The new drug marketing application for CMAB007 has been submitted to the NMPA in October 2021. It is expected to be approved for commercialisation in the first quarter of 2023. We expect that upon commercialisation, CMAB007 will be the first home-made omalizumab launched in the domestic market. The Company has been seeking for cooperation with China's leading drug manufacturers for the sale of CMAB007, aiming to achieve rapid increase in the sales volume of CMAB007. It is expected that CMAB007 will expand its indications to chronic idiopathic urticarial, seasonal allergic rhinitis and food allergies in the future.

CMAB009 (cetuximab)

CMAB009 (cetuximab), a recombinant anti-EGFR chimeric monoclonal antibody, is our new drug candidate based on cetuximab for first-line treatment of metastatic colorectal cancer (“mCRC”) in combination with FOLFIRI. CMAB009 is the first NMPA approved chimeric anti-EGFR antibody for clinical trial developed in China by a local Chinese company. CMAB009 uses the CHO expression system, which is different from the mouse myeloma cell SP2/0 expression system used in marketed cetuximab products. The safety and efficacy of CMAB009 have been confirmed from the results of two completed clinical trials on a total of 530 subjects, which were the largest clinical trials of anti-EGFR mAb developed in China by a local Chinese company. Based on our clinical trial results compared to published clinical trial results for currently marketed cetuximab products, CMAB009 significantly reduces immunogenicity and decreases the incidence of adverse reactions, such as severe hypersensitivity. We believe that CMAB009 is safer than, and as effective as, currently marketed cetuximab drugs for the treatment of mCRC.

During the Reporting Period, CMAB009 was under phase III clinical trials for colorectal cancer, completed case recruitment and finalising NDA data organisation, analysis and collection. We expect to file the new drug marketing application with the NMPA in the fourth quarter of 2022 upon completion of clinical observation and data analysis of all cases. We are also preparing for clinical trials of other indications of CMAB009. Currently, we expect that CMAB009 may be approved by the NMPA for marketing in the first quarter of 2024.


Other Product Candidates

CMAB807 (Denosumab) is a human IgG2 monoclonal antibody with affinity and specificity for human RANKL (receptor activator of nuclear factor kappa-B ligand), which is a transmembrane or soluble protein essential for the formation, function, and survival of osteoclasts, the cells responsible for bone resorption. CMAB807 prevents RANKL from activating its receptor, RANK, on the surface of osteoclasts and their precursors. Prevention of the RANKL/RANK interaction inhibits osteoclast formation, function, and survival, thereby decreasing bone resorption and increasing bone mass and strength in both cortical and trabecular bones. CMAB807 is currently under phase III clinical trials for osteoporosis, and has completed case recruitment. We expect that CMAB807 will be approved by NMPA for marketing in the fourth quarter of 2024 for the indication of osteoporosis.

We have also developed a dosage form of CMAB807, i.e. CMAB807X (denosumab), for the treatment of tumor bone metastasis and conducted pre-clinical study, and obtained the Clinical Trial Approval Notice. We expect that phase III clinical trials for tumor bone metastasis will be launched in the fourth quarter of 2023. It is currently expected that CMAB807X will be approved by NMPA for marketing in the fourth quarter of 2027 for the treatment for indication of tumor bone metastasis.

CMAB819 (nivolumab) is our biosimilar drug candidate currently undergoing phase I clinical trial. CMAB819 has been approved by the NMPA for clinical trial. We have commenced the phase I clinical trial. We expect that CMAB819 may be approved by the NMPA for marketing in the fourth quarter of 2027. CMAB819 is indicated for the treatment of metastatic non-small cell lung cancer, hepatocellular carcinoma and head and neck squamous cell carcinomas (HNSCC).

CMAB017 (anti-EGFR probody) is an innovative probody drug, and has been approved by the NMPA for clinical trials for the treatment of advanced solid tumors, including but not limited to colorectal cancer, head and neck squamous cell carcinomas and esophageal squamous cell carcinoma. Results of the completed experimental study on tissue distribution of tumor-bearing mice show that CMAB017 concentrates locally in tumor 24-72 hours after administration. We expect to commence phase III clinical trial in the fourth quarter of 2024. We expect that CMAB017 may be approved by the NMPA for marketing in the fourth quarter of 2028. Regarding CMAB017, the design of blocking peptide is expected to significantly reduce adverse skin reactions, gastrointestinal mucosa, etc. The selection of IgG1 constant region can enhance the effect mediated by Fc fragment of antibody and thus improve the curative effect. CMAB017 is a biological class I new drug with better efficacy and safety than similar products available on the market, and it is expected that more new probody drugs will be developed by leveraging the research and development platform of CMAB017. CMAB017 is indicated for the treatment of advanced solid tumors, including but not limited to colorectal cancer, head and neck squamous cell carcinomas and esophageal squamous cell carcinoma.



CMAB015 (Secukinumab) is a biosimilar candidate for secukinumab, and has been approved by the NMPA for clinical trials of the treatment of psoriasis and ankylosing spondylitis. We expect that CMAB015 may be approved by the NMPA for marketing in the fourth quarter of 2025. CMAB015 targets interleukin 17A (IL-17A) for treating psoriasis and ankylosing spondylitis. Secukinumab is the most effective curer for psoriasis at present, which offers significant efficacy and guarantees much more stable condition after drug withdrawal compared with peers.

CMAB022 is a candidate biosimilar product of stelara® (ustekinumab). Ustekinumab is a monoclonal antibody targeting interleukin-12 (IL-12) and interleukin-23 (IL-23). It inhibits these two proinflammatory cytokines by binding to the P40 subunit shared by IL-12 and IL-23 and preventing them from binding to the cell surface IL-12 receptor β 1. IL-12 and IL-23 are two natural proteins, which play a key role in immune-mediated inflammatory diseases, including plaque psoriasis, psoriatic arthritis and Crohn's disease, indications include: moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy; adults with active psoriatic arthritis (PsA); adults with active ankylosing spondylitis (AS); adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation. The pilot processes are currently in development. We expect to apply for clinical trials in the first quarter of 2023 and CMAB022 may be approved by the NMPA for marketing in the third quarter of 2027.

CMAB018 is a biosimilar candidate for mepolizumab, which is under preclinical study. At present, the screening of high expression engineering cells and the establishment of engineering cell bank have been completed, the research on production process is in progress and it is expected that we will apply for clinical trial in the first quarter of 2023. We expect that CMAB018 may be approved by the NMPA for marketing in the fourth quarter of 2027. CMAB018 targets interleukin 5 (IL-5) in treating severe asthma and eosinophilic granulomatous polyangiitis.

CMAB810 (pertuzumab) is our pre-clinical trial biosimilar drug candidate. The related screening processes, the establishment of a cell bank, and a lab-scale process for CMAB810 have been completed. We are carrying out preclinical animal experiments for CMAB810 and expect to apply for clinical trials in the fourth quarter of 2022. We expect that CMAB810 may be approved by the NMPA for marketing in the third quarter of 2029. CMAB810 is indicated for the treatment of breast cancer.

CMAB816 (canakinumab) is our pre-clinical trial biosimilar drug candidate. The related screening processes and the establishment of cell bank have been completed. It is expected to apply for clinical trials in the third quarter of 2023. We expect that CMAB816 may be approved by the NMPA for marketing in the third quarter of 2029. CMAB816 is indicated for the treatment of periodic fever syndrome and systemic juvenile idiopathic arthritis.

Research and development of new drug candidates

We have launched a series of follow-up R&D on new antibody drugs for the treatment of autoimmune diseases and/or tumor diseases. We expect to successfully complete the screening of several new antibody drugs, cell banking and even start pre-clinical animal experiments, thus further expand our product line and provide sufficient drug candidate pipeline expansion for our long-term development.

Research and development system

We have developed efficient R&D capabilities, broad and advanced preparation technologies, and low-cost drug production capabilities that will allow us to offer high quality and affordable innovative biopharmaceutical products to patients in China and other emerging markets. Within our product pipeline, CMAB008 has been marketed and commercialized, CMAB007 has filed NDA application, successfully passed site verification and will soon be approved for marketing, while CMAB009 and CMAB807 are under late stage of phase III clinical trials. We also own a number of patents for our core technologies, including antibody engineering and humanization technologies, efficient expression vector construction technologies, efficient clone screening technologies, as well as a proprietary R&D animal model. Our R&D activities are carried out by three core teams: basic R&D, clinical trials, and industrialized good manufacturing practices (“GMP”). The operations, design, and construction needs of these three core teams are supported by an assisting engineering team. Our R&D teams consist of professionals who have extensive industry experience in biologics R&D and have gained valuable work experience at global pharmaceutical companies. Employees in our R&D teams possess strong academic backgrounds from leading institutions in immunology, molecular biology, oncology or monoclonal antibody development.

DRUG CANDIDATES COMMERCIALIZATION AND PRODUCTION FACILITIES CONSTRUCTION

Existing production facilities

Our production site in Taizhou has two buildings of 30,000 square meters in total and houses our mAb production facilities. The two buildings are equipped with production facilities currently in operation, including (i) four 3×1,500L antibody bioreactor systems and related purification lines, (ii) an injection vial filling line capable of manufacturing four million units per annum and (iii) a pre-filled syringes production line capable of manufacturing one million units per annum. Our production facilities have successfully passed the GMP compliance inspection for CMAB008 by the Jiangsu Provincial Drug Administration and have commenced commercial production.

Construction of new production facilities

We constructed new production facilities on a parcel of industrial land of approximately 100,746 square meters in the Taizhou Hi-tech Zone. Our expansion plan includes the construction of (i) large-scale monoclonal antibody drug substance production lines with scale of each cell reactor reaching 7,500L and 18,000L, respectively, and (ii) two drug product filling lines which have already completed the construction of the plant. In particular, the Company's large-scale GMP production line in construction has been under installation and commissioning, which is expected to be put into operation by the end of 2022 and will bring the aggregate scale of our cell reactor to over 40,000 liters.

Marketing and distribution

Further, during the rapid growth of the pharmaceutical market in China, the central procurement under the medical insurance that may be extended to cover biological drugs in the future and the increased effort in national negotiations on medical insurance will restructure the pharmaceutical market in China to a large extent. We will actively participate in the national medical reform with our advantages in advanced technology, quality and cost and capture the opportunities presented during the policy reform so as to capture the huge unmet market demand in China. At the same time, we have also initiated our global market expansion and accelerated the registration and launching of our drugs in the international market.

We have been striving to choose the optimal business model to promote the commercialisation of our products based on changes in China's overall pharmaceutical market and its segments, and adopt corresponding sales and marketing strategies, including cooperation with sales partners and establishment of an in-house sales team. Joining hands with our sales partners, we will focus on precision marketing through academic promotion and center around increasing knowledge and awareness of the clinical benefits of our pharmaceuticals among medical professionals. We intend to focus on hospitals with potential clinical demand for our products as our primary customer base. We intend to continue to communicate frequently with major hospitals in China to understand these hospitals and their doctors' academic views on antibody drugs and patient demands, and meet industry experts regularly to understand industry trends. We will continue to participate in academic conferences, seminars and symposia, which include large-scale national and provincial conferences organized by the Chinese Medical Association or its local chapters, as well as smaller events tailored to specific cities and hospital departments to promote our brand awareness. We expect to implement certain procedures to ensure that the academic promotion and general marketing efforts made by us and our business partners are in compliance with applicable laws and regulations.

We expect to sell our products to (i) distributors that sell our products to hospitals and (ii) direct-to-patient pharmacies and others. We are establishing our network of distributors for CMAB008 in accordance with the national drug sales regulations. Our distribution model is consistent with customary industry practice and serves to ensure efficient coverage of our sales network while controlling our cost of distribution and account receivables. We intend to select sales service providers and distributors according to their qualifications, reputation, market coverage and sales experience. Sales service providers are expected to have long-term experience in terms of prescription drug sales and a proven track record, while a distributor must maintain its business license and other requisite licenses and permits. A distributor must also maintain extensive hospital coverage in the designated region. A distributor must be capable of delivering our products to covered hospitals in a safe and timely manner. We plan to actively monitor the inventory levels of our distributors to increase the efficiency of our distribution network.

Quality assurance

We believe that an effective quality management system for our raw materials, equipment and finished products is critical to ensure the quality of our services and maintain our reputation and success. To ensure that our products and services consistently meet high industry standards and requirements, we have also established a company-level quality assurance department to inspect the quality of our products and services. It is also responsible for the approval, organization and coordination of quality control and quality assurance procedures within each subsidiary. Facilities and equipment are subject to inspection measures such as united registrar systems, factory acceptance testing, site acceptance testing, installation qualification, operator qualification, performance qualification, and regular maintenance throughout their entire life cycles. Our manufacturing business lines are inspected in accordance with the PRC national laboratory quality control standard and the GMP management requirements; our research and development business lines are also inspected in accordance with the GMP management requirements.

FUTURE AND OUTLOOK

We leverage our efficient sales system with a focus on niche markets to capture the opportunities presented in the pharmaceutical reform in China.

Under the implementation of the new medical insurance policy in recent years, the pharmaceutical market in China is undergoing significant market restructuring. Companies with more competitive advantages in quality and pricing have benefited greatly from the negotiations on medical insurance price between the National Healthcare Security Administration and regional healthcare security administrative bodies at all levels and negotiations in relation to central procurement for drugs covered under the medical insurance. As a result, the overall market penetration has increased significantly during the reformation. This trend will drive the development of the pharmaceutical market in China for a long time into the future. Riding on the trend of the overall pharmaceutical policy reform, we will build a sales team in China with high efficiency and academic promotion as its core strategy either by ourselves or together with sales partners, focusing on niche markets, such as gastroenterology, respiratory and allergic diseases, skin disease, rheumatology and oncology, with an aim to promote our products and cultivate the practice of antibody drugs application. We will actively monitor, and participate in, the negotiations of medical insurance, especially focusing on capturing the huge potentials brought by the negotiations of central procurement for biological products under the medical insurance. Relying on the significant advantages of our drugs in terms of quality and cost, we will capture opportunities presented in the significant increase in market penetration caused by the policy reform, effectively satisfying the unmet market demand in China in respect of biological agents with high quality products and ultimately benefiting patients.

The antibody drugs development in overseas markets has shown a rapid increase resulting in a huge unmet global market demand for antibody drugs, especially for those with PIC/s as the core. In light of the policy reform in China, the economies of scale of antibody drugs will greatly enhance the global competitiveness of Chinese antibody drugs. In view of this, we will work closely with our overseas market expansion partners to initiate new drug registration and launching new drugs in different countries and regions in a comprehensive and flexible manner with multiple products, with an aim to promote our products' global presence and accelerate their growth in the global market.

Continue to advance the clinical research and commercialization of our drug candidates

Over the short-term, we intend to focus on market exploration and sales of CMAB008, and completing clinical trials and the eventual commercialization of our current pipeline of drug candidates, particularly CMAB007, CMAB009, CMAB807, CMAB015 and CMAB022. To bring our products to market, we aim to reinforce our R&D teams, particularly the clinical medicine team, through the provision of regular professional training and pushing ahead with the clinical trials for product candidates. We are working with partners to build a sales team composed of professionals with extensive academic promotion experience and strong competence. Our goal is to generate stable revenue stream and profitability through cooperation with leading enterprises in China and cultivating our in-house sales team to enhance our commercialisation capacity.

Continue to maintain investments in advanced technologies and product development

We believe R&D is the key element to support our future growth and our ability to maintain our competitiveness in a global biopharmaceutical market. We plan to upgrade the development of our integrated technological platforms from molecular design to commercialized production, and focus on the R&D of biologics with huge clinical demand and the potential for sustained and rapid growth in China. In order to capture new opportunities in the biopharmaceutical market, we plan to continue increasing our investment in innovative technologies for the development of drugs with improved curative effects and less toxic side effects in order to maintain our industry leading position. We also expect to invest in talent to expand and enhance our R&D team.

Continue to attract and nurture high quality talent to support our rapid growth

Recruiting and retaining high quality scientific and technological talent as well as other leaders in R&D technology will be key to our success. We plan to leverage our close cooperation with elite universities in China and internationally to recruit and develop outstanding R&D personnel. We also plan to provide systematic and sophisticated training and development programs to our research teams in order to enhance and optimize their scientific and technical abilities to benefit our Company. Part of this strategy involves the creation of an incentive scheme to retain and motivate high-performing team members.

Establish global brand awareness and foster deeper and more extensive cooperative relationship with domestic and overseas renowned pharmaceutical companies

To build our brand internationally and to support our sustainable growth, we plan to in-license products from global pharmaceutical companies for sales in China and/or to transfer or out-license overseas product rights of certain of our drug candidates to other pharmaceutical companies. We have established collaborative partnerships with domestic and foreign pharmaceutical companies with overseas channel resources, and constantly seek more opportunities to cooperate with potential partners with sales resources, in order to enter and expand our market share in markets outside of China and to further broaden the geographic coverage of our business. As part of this strategy, we may take advantage of strategic opportunities for mergers and acquisitions internationally to expand our pipeline of products for R&D development and sales in overseas markets.

FINANCIAL INFORMATION

The financial information set out below in this announcement represents an extract from the interim condensed consolidated financial information, which is unaudited but has been reviewed by the Audit Committee.

FINANCIAL REVIEW

The following table summarizes our results of operations for the six months ended June 30, 2022 and 2021:

	For the six months ended June 30,			
	2022	2021	Change	Change
	RMB'000	RMB'000	RMB'000	(%)
	(unaudited)	(unaudited)		
Revenue	28,847	81,246	(52,399)	(64.5)
Cost of sales	(11,054)	(16,769)	5,715	(34.1)
Gross profit	17,793	64,477	(46,684)	(72.4)
Other income	12,450	3,558	8,892	249.9
Other gains and losses	(2,862)	(4,719)	1,857	(39.4)
Selling and distribution expenses	(15,264)	–	(15,264)	N/A
Research and development expenses	(77,990)	(163,455)	85,465	(52.3)
Administrative expenses	(47,832)	(43,755)	(4,077)	9.3
Finance costs	(3,104)	(1,267)	(1,837)	145.0
Loss before tax	(116,809)	(145,161)	28,352	(19.5)
Income tax expense	–	–	–	N/A
Loss and total comprehensive expense for the period	(116,809)	(145,161)	28,352	(19.5)
Attributable to:				
Owners of the Company	(116,809)	(145,161)	28,352	(19.5)
Loss per share attributable to ordinary equity holders of the Company				
– Basic	RMB (0.03)	RMB (0.04)		
– Diluted	RMB (0.03)	RMB (0.04)		

Revenue

The Group's revenue decreased by 64.5% from RMB81.2 million for the six months ended June 30, 2021 to RMB28.8 million for the six months ended June 30, 2022, primarily attributable to the completion of the transfer of an intellectual property for the six months ended June 30, 2021. Set out below are the components of revenue for the periods indicated:

	For the six months ended June 30,	
	2022	2021
	RMB'000	RMB'000
	(unaudited)	(unaudited)
Revenue from the sale of pharmaceutical products	4,203	–
Revenue from the exclusive right for the commercialisation in Mainland China	3,538	–
Revenue from the contract development and manufacturing agreement	21,106	–
Revenue from the transfer of an intellectual property	<u>–</u>	<u>81,246</u>
	<u>28,847</u>	<u>81,246</u>

Cost of sales

The Group's cost of sales decreased by 34.1% from RMB16.8 million for the six months ended June 30, 2021 to RMB11.1 million for the six months ended June 30, 2022, primarily attributable to the decrease in cost related to the transfer of an intellectual property.

OTHER INCOME

Other income of the Group increased by 249.9% from RMB3.6 million for the six months ended June 30, 2021 to RMB12.5 million for the six months ended June 30, 2022, which was primarily due to a significant increase in government grants received during the Reporting Period.

Set out below are the components of other income for the periods indicated:

	For the six months ended June 30,	
	2022	2021
	<i>RMB'000</i>	<i>RMB'000</i>
	(unaudited)	(unaudited)
Bank interest income	244	1,043
Government grants and subsidies related to income	12,206	2,515
	<u>12,450</u>	<u>3,558</u>

OTHER GAINS AND LOSSES

Other gains and losses of the Group decreased by 39.4% from losses of RMB4.7 million for the six months ended June 30, 2021 to losses of RMB2.9 million for the six months ended June 30, 2022, which was primarily due to a significant decrease in foreign exchange losses as a result of the decrease in cash and bank balances denominated in the U.S. dollar during the Reporting Period.

Set out below are the components of other gains and losses for the periods indicated:

	For the six months ended June 30,	
	2022	2021
	<i>RMB'000</i>	<i>RMB'000</i>
	(unaudited)	(unaudited)
Net foreign exchange losses	(2,862)	(4,646)
Others	–	(73)
	<u>(2,862)</u>	<u>(4,719)</u>

RESEARCH AND DEVELOPMENT EXPENSES

Research and development expenses of pipelines of the Group decreased by 52.3% from RMB163.5 million for the six months ended June 30, 2021 to RMB78.0 million for the six months ended June 30, 2022, primarily due to no intellectual property license-in expenses incurred during the Reporting Period.

The Group's research and development expenses mainly include contracting costs, raw materials and consumables, staff costs, depreciation, intellectual property license-in expenses and others.

Set out below are the components of research and development expenses for the periods indicated:

	For the six months ended June 30,	
	2022	2021
	<i>RMB'000</i>	<i>RMB'000</i>
	(unaudited)	(unaudited)
Contracting costs	34,641	51,999
Raw materials and consumables	9,364	13,090
Staff costs	22,856	24,235
Depreciation	6,616	3,895
Intellectual property license-in expenses	–	66,038
Others	4,513	4,198
	<hr/>	<hr/>
Total	77,990	163,455
	<hr/> <hr/>	<hr/> <hr/>

ADMINISTRATIVE EXPENSES

Administrative expenses of the Group increased by 9.3% from RMB43.8 million for the six months ended June 30, 2021 to RMB47.8 million for the six months ended June 30, 2022, primarily due to a slight increase in staff cost and depreciation.

Administrative expenses of the Group primarily comprise of staff salary and benefit costs of our administrative personnel, depreciation and others.

Set out below are the components of administrative expenses for the periods indicated:

	For the six months ended June 30,	
	2022	2021
	<i>RMB'000</i>	<i>RMB'000</i>
	(unaudited)	(unaudited)
Staff cost	21,698	19,414
Depreciation	16,529	14,190
Others	9,605	10,151
	<hr/>	<hr/>
Total	47,832	43,755
	<hr/> <hr/>	<hr/> <hr/>

FINANCE COSTS

Finance costs of the Group increased by 145.0% from RMB1.3 million for the six months ended June 30, 2021 to RMB3.1 million for the six months ended June 30, 2022, which was primarily due to the increase in interest on bank and other borrowings incurred during the Reporting Period.

The Group's finance costs mainly include interests on bank and other borrowings and lease liabilities.

Set out below are the components of finance costs for the periods indicated:

	For the six months ended June 30,	
	2022	2021
	<i>RMB'000</i>	<i>RMB'000</i>
	(unaudited)	(unaudited)
Interest on bank and other borrowings	1,674	—
Interest on lease liabilities	1,430	1,267
	<hr/>	<hr/>
Total	3,104	1,267
	<hr/> <hr/>	<hr/> <hr/>

LIQUIDITY AND CAPITAL RESOURCES

Our trade receivables increased by 385.5% from RMB0.8 million as at December 31, 2021 to RMB3.9 million as at June 30, 2022, which was primarily due to the increase in the revenue from the sale of pharmaceutical products. Our inventories increased by 51.0% from RMB53.2 million as at December 31, 2021 to RMB80.4 million as at June 30, 2022, which was primarily due to the increase in raw materials and consumables to meet the needs of production. Our contract costs decreased by 100.0% from RMB9.2 million as at December 31, 2021 to Nil as at June 30, 2022, which was primarily due to the recognition of revenue from the contract development and manufacturing agreement during the Reporting Period which converts such contract costs to cost of sales. Our pledged bank deposits decreased by 100.0% from RMB34.7 million as at December 31, 2021 to Nil as at June 30, 2022, which was primarily due to the expiration of the euro letter of credit in connection with the purchase of plant and equipment.

Set out below is an analysis of the liquidity and capital resources at the dates indicated:

	At June 30, 2022 RMB'000 (unaudited)	At December 31, 2021 RMB'000 (audited)	Change (%)
Trade receivables	3,850	793	385.5
Prepayments and other receivables	50,283	58,846	(14.6)
Amounts due from a related party	9,452	9,452	–
Inventories	80,358	53,211	51.0
Contract costs	–	9,164	(100.0)
Pledged bank deposits	–	34,748	(100.0)
Cash and bank balances	<u>80,286</u>	<u>81,556</u>	<u>(1.6)</u>
Total	<u><u>224,229</u></u>	<u><u>247,770</u></u>	<u><u>(9.5)</u></u>

INDEBTEDNESS

As of June 30, 2022, we had non-trade amounts due to a related party of RMB0.3 million, lease liabilities of RMB45.6 million and interest-bearing bank and other borrowings of RMB81.1 million. As of the same date, none of our existing indebtedness included any material covenants or covenants that could potentially limit our ability to incur new indebtedness.

Set out below is a breakdown of our outstanding non-trade amounts due to a related party, lease liabilities and interest-bearing bank and other borrowings at the dates indicated:

	At June 30, 2022	At December 31, 2021
	RMB'000	RMB'000
	(unaudited)	(audited)
Unsecured and unguaranteed amounts due to Biomabs	313	739
Lease liabilities	45,560	45,690
Secured loans from the bank	29,650	–
Unsecured loans from the third party	51,475	–

As at June 30, 2022, we, as a lessee, had outstanding lease liabilities for the remaining terms of relevant lease agreements (excluding our contingent rental agreements) in an aggregate amount of approximately RMB45.6 million.

CONTINGENT LIABILITIES, CHARGE OF ASSETS AND GUARANTEES

As at June 30, 2022, the 100,746-square-meter land located at No. 288 Xiangtai Road of the Taizhou Hi-tech Zone with a carrying amount of approximately RMB35.5 million and several production and office buildings with a total floor area of 50,835 square meters located in the same address above and with a carrying amount of approximately RMB117.9 million were pledged to Bank of Communications Co., Ltd. Taizhou Branch as security for the bank loans of the Group amounting to RMB29.7 million as of June 30, 2022. For details, please refer to note 18 to the interim condensed consolidated financial information.

Saved as disclosed, we did not have any outstanding debt securities, charges, mortgages, or other similar indebtedness, hire purchase commitments, liabilities under acceptances (other than normal trade bills), acceptance credits, which are guaranteed, unguaranteed, secured or unsecured, any guarantees or other material contingent liabilities.

CAPITAL STRUCTURE

There were no changes in the capital structure of the Group during the Reporting Period. The share capital of the Group only comprises ordinary Shares. As at June 30, 2022, the total issued share capital of the Company was US\$412,408 divided into 4,124,080,000 Shares.

The capital structure of the Group was 47.6% debt and 52.4% equity as at June 30, 2022, compared with 33.1% debt and 66.9% equity as at December 31, 2021.

FOREIGN EXCHANGE

Foreign currency risk refers to the risk of loss resulting from changes in foreign currency exchange rates. Fluctuations in exchange rates between RMB and other currencies in which our Group conducts business may affect our financial condition and results of operation. The Group mainly operates in the PRC and is exposed to foreign exchange risk arising from various currency exposures, primarily with respect to Hong Kong dollars and the U.S. dollars. The conversion of foreign currencies into RMB, including Hong Kong dollars and the U.S. dollars, has been based on rates set by the People's Bank of China. The Group primarily limits our exposure to foreign currency risk by closely monitoring the foreign exchange market. During the Reporting Period, the Group did not enter into any currency hedging transactions.

GEARING RATIO

Gearing ratio is calculated using total liabilities divided by total assets and multiplied by 100%. As at June 30, 2022 the gearing ratio of the Group was 47.6% (unaudited) (as at December 31, 2021: 33.1% (audited)).

The following table sets forth our other key financial ratios as of the dates indicated.

	At June 30, 2022 (unaudited)	At December 31, 2021 (audited)
Current ratio ⁽¹⁾	1.0	1.1
Quick ratio ⁽²⁾	0.6	0.8

Notes:

- (1) Current ratio represents current assets divided by current liabilities as of the same date.
- (2) Quick ratio represents current assets less inventories and divided by current liabilities as of the same date.

Our current ratio decreased from 1.1 as of December 31, 2021 to 1.0 as of June 30, 2022, and our quick ratio decreased from 0.8 as of December 31, 2021 to 0.6 as of June 30, 2022, primarily due to the Company's funds being used for operation and development of the Group according to the respective intended purposes.

INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the six months ended 30 June 2022

	<i>Notes</i>	2022 (Unaudited) RMB'000	2021 (Unaudited) RMB'000
Revenue	5	28,847	81,246
Cost of sales		<u>(11,054)</u>	<u>(16,769)</u>
Gross profit		17,793	64,477
Other income	6	12,450	3,558
Other gains and losses	7	(2,862)	(4,719)
Selling and distribution expenses		(15,264)	–
Research and development expenses		(77,990)	(163,455)
Administrative expenses		(47,832)	(43,755)
Finance costs	8	<u>(3,104)</u>	<u>(1,267)</u>
Loss before tax	9	(116,809)	(145,161)
Income tax expense	10	<u>–</u>	<u>–</u>
Loss and total comprehensive expense for the period		<u>(116,809)</u>	<u>(145,161)</u>
Attributable to:			
Owners of the Company		<u>(116,809)</u>	<u>(145,161)</u>
Loss per share attributable to ordinary equity holders of the Company	12		
– Basic		<u>RMB (0.03)</u>	<u>RMB (0.04)</u>
– Diluted		<u>RMB (0.03)</u>	<u>RMB (0.04)</u>

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

30 June 2022

	<i>Notes</i>	30 June 2022 (Unaudited) RMB'000	31 December 2021 (Audited) RMB'000
Non-current assets			
Plant and equipment	<i>13</i>	596,266	483,673
Right-of-use assets		72,809	77,374
Other non-current assets	<i>14</i>	44,289	90,674
Rental deposit to a related party		411	411
		<hr/>	<hr/>
Total non-current assets		713,775	652,132
Current assets			
Trade receivables	<i>15</i>	3,850	793
Prepayments and other receivables	<i>16</i>	50,283	58,846
Amounts due from a related party	<i>21</i>	9,452	9,452
Inventories		80,358	53,211
Contract costs		–	9,164
Pledged bank deposits		–	34,748
Cash and bank balances		80,286	81,556
		<hr/>	<hr/>
Total current assets		224,229	247,770

	<i>Notes</i>	30 June 2022 (Unaudited) RMB'000	31 December 2021 (Audited) RMB'000
Current liabilities			
Trade and other payables	<i>17</i>	143,372	139,827
Amounts due to a related party	<i>21</i>	47,544	47,964
Lease liabilities to third parties		7,171	5,084
Lease liability to a related party	<i>21</i>	6,219	4,199
Contract liabilities		9,465	21,440
Deferred income		9,250	16,490
		<hr/>	<hr/>
Total current liabilities		223,021	235,004
		<hr/>	<hr/>
Net Current Assets		1,208	12,766
		<hr/>	<hr/>
Total Assets Less Current Liabilities		714,983	664,898
		<hr/>	<hr/>
Non-current liabilities			
Deferred income		10,000	10,000
Interest-bearing bank and other borrowings	<i>18</i>	81,125	–
Contract liabilities		100,560	16,510
Lease liabilities to third parties		25,701	27,926
Lease liability to a related party		6,469	8,481
		<hr/>	<hr/>
Total non-current liabilities		223,855	62,917
		<hr/>	<hr/>
Net Assets		491,128	601,981
		<hr/> <hr/>	<hr/> <hr/>
Capital and reserves			
Share capital		2,804	2,804
Reserves		488,324	599,177
		<hr/>	<hr/>
Total Equity		491,128	601,981
		<hr/> <hr/>	<hr/> <hr/>

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the six months ended 30 June 2022

	Share capital <i>RMB'000</i>	Share premium <i>RMB'000</i>	Other reserve <i>RMB'000</i>	Share-option reserve <i>RMB'000</i>	Accumulated losses <i>RMB'000</i>	Total equity <i>RMB'000</i>
At 1 January 2022 (Audited)	2,804	1,400,504	(32,763)	43,935	(812,499)	601,981
Loss and total comprehensive expense for the period (Unaudited)	-	-	-	-	(116,809)	(116,809)
Recognition of equity-settled share-based compensation (Unaudited)	-	-	-	5,956	-	5,956
At 30 June 2022 (Unaudited)	<u>2,804</u>	<u>1,400,504</u>	<u>(32,763)</u>	<u>49,891</u>	<u>(929,308)</u>	<u>491,128</u>
At 1 January 2021 (Audited)	2,804	1,400,504	(32,763)	31,695	(520,755)	881,485
Loss and total comprehensive expense for the period (Unaudited)	-	-	-	-	(145,161)	(145,161)
Recognition of equity-settled share-based compensation (Unaudited)	-	-	-	6,570	-	6,570
At 30 June 2021 (Unaudited)	<u>2,804</u>	<u>1,400,504</u>	<u>(32,763)</u>	<u>38,265</u>	<u>(665,916)</u>	<u>742,894</u>

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

For the six months ended 30 June 2022

	<i>Notes</i>	2022 (Unaudited) RMB'000	2021 (Unaudited) RMB'000
CASH FLOWS FROM OPERATING ACTIVITIES			
Loss before tax		(116,809)	(145,161)
Adjustments for:			
Bank interest income	6	(244)	(1,043)
Finance costs	8	3,104	1,267
Depreciation of plant and equipment	9	20,979	14,085
Depreciation of right-of-use assets	9	4,565	4,569
Loss on disposal of plant and equipment	9	–	73
Net foreign exchange losses	7	2,862	4,646
Share-based payment expenses	9	5,956	6,570
		(79,587)	(114,994)
Increase in inventories		(27,147)	(4,237)
Decrease in contract costs		9,164	15,919
Increase in trade receivables		(3,057)	(11,468)
Decrease/(increase) in prepayments and other receivables		8,563	(6,718)
Decrease in other non-current assets		1,348	2,794
Increase in amounts due to a related party		1,802	50,347
Increase in trade and other payables		13,034	12,494
Increase/(decrease) in contract liabilities		72,075	(53,914)
(Decrease)/increase in deferred income		(7,240)	1,400
Net cash flows used in operating activities		(11,045)	(108,377)
CASH FLOWS FROM INVESTING ACTIVITIES			
Interest received from bank		244	1,043
Purchase of plant and equipment		(98,059)	(61,230)
Disposal of plant and equipment		–	42
Withdraw of pledged bank deposits		34,748	–
Net cash flows used in investing activities		(63,067)	(60,145)

	2022	2021
	(Unaudited)	(Unaudited)
	RMB'000	RMB'000
CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from bank and other borrowings	77,332	–
Interest paid	(637)	(1,294)
Repayments to a related party	(2,222)	(383)
Repayments of principal portion of lease liabilities	(1,460)	(2,809)
	<u>73,013</u>	<u>(4,486)</u>
Net cash flows from/(used in) financing activities		
NET DECREASE IN CASH AND		
CASH EQUIVALENTS		
	(1,099)	(173,008)
Cash and cash equivalents at beginning of period	81,556	484,846
Effects of foreign exchange rate changes, net	(171)	(4,660)
	<u>80,286</u>	<u>307,178</u>
CASH AND CASH EQUIVALENTS AT END OF		
PERIOD		

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

30 June 2022

1. GENERAL INFORMATION

Mabpharm Limited (the “**Company**”) was incorporated in the Cayman Islands as an exempted company with limited liability on 1 June 2018, and its shares are listed on The Stock Exchange of Hong Kong Limited on 31 May 2019. The address of the registered office is 190 Elgin Avenue, George Town, Grand Cayman KY1-9008, Cayman Islands and the principal place of business is located at Block G79, Lujia Road East, Koutai Road West, China Medical City, Taizhou, the People’s Republic of China (the “**PRC**”).

The Company is an investment holding company. The Company and its subsidiaries (the “**Group**”) are principally engaged in research, development and production of monoclonal antibody drugs for cancers and autoimmune diseases and transfer of intellectual property.

The immediate holding company of the Company is Asia Mabtech Limited, a limited liability company incorporated in the British Virgin Islands, which is ultimately controlled by Mr. Guo Jianjun.

2. BASIS OF PREPARATION

The interim condensed consolidated financial information for the six months ended 30 June 2022 has been prepared in accordance with IAS 34 *Interim Financial Reporting*. The interim condensed consolidated financial information does not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group’s annual consolidated financial statements for the year ended 31 December 2021.

This interim condensed consolidated financial information is presented in Renminbi (“**RMB**”) and all values are rounded to the nearest thousand except when otherwise indicated.

3. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

The accounting policies adopted in the preparation of the interim condensed consolidated financial information are consistent with those applied in the preparation of the Group’s annual consolidated financial statements for the year ended 31 December 2021, except for the adoption of the following revised International Financial Reporting Standards (“**IFRSs**”) for the first time for the current period’s financial information.

Amendments to IFRS 3	<i>Reference to the Conceptual Framework</i>
Amendments to IAS 16	<i>Property, Plant and Equipment: Proceeds before Intended Use</i>
Amendments to IAS 37	<i>Onerous Contracts – Cost of Fulfilling a Contract</i>
<i>Annual Improvements to IFRSs 2018-2020</i>	Amendments to IFRS 1, IFRS 9, Illustrative Examples accompanying IFRS 16, and IAS 41

The adoption of these revised standards has had no significant financial effect on the Group’s interim condensed consolidated financial information.

4. OPERATING SEGMENT INFORMATION

Segment information

For the purpose of resources allocation and performance assessment, the key management of the entities and business comprising the Group, being the chief operating decision maker, reviews the consolidated results when making decisions about allocating resources and assessing performance of the Group as a whole and hence, the Group has only one reportable segment and no further analysis of this single segment is presented.

Geographical information

During the reporting period, all of the Group's revenue was derived from customers located in the PRC and the Group's non-current assets are substantially located in the PRC, accordingly, no geographical information in accordance with IFRS 8 *Operating Segments* is presented.

Information about a major customer

Revenue of approximately RMB21,106,000 (unaudited) was derived from a contract development and manufacturing agreement with a single customer (during the six months ended 30 June 2021: RMB81,246,000 (unaudited) was derived from an intellectual property transfer agreement to a single customer).

5. REVENUE

An analysis of revenue is as follows:

	For the six months ended 30 June	
	2022 RMB'000 (Unaudited)	2021 RMB'000 (Unaudited)
Revenue from contracts with customers	<u>28,847</u>	<u>81,246</u>

Disaggregated revenue information for revenue from contracts with customers

	For the six months ended 30 June	
	2022 RMB'000 (Unaudited)	2021 RMB'000 (Unaudited)
<i>Revenue from contracts with customers</i>		
Revenue from the sale of pharmaceutical products	4,203	–
Revenue from the exclusive right for the commercialisation in Mainland China	3,538	–
Revenue from the contract development and manufacturing agreement	21,106	–
Revenue from the transfer of an intellectual property	<u>–</u>	<u>81,246</u>
	<u>28,847</u>	<u>81,246</u>

Geographical market

Mainland China	<u>28,847</u>	<u>81,246</u>
----------------	---------------	---------------

Timing of revenue recognition

Over time	3,538	–
At a point in time	<u>25,309</u>	<u>81,246</u>
	<u>28,847</u>	<u>81,246</u>

6. OTHER INCOME

	For the six months ended 30 June	
	2022	2021
	<i>RMB'000</i>	<i>RMB'000</i>
	(Unaudited)	(Unaudited)
Bank interest income	244	1,043
Government grants and subsidies related to income	12,206	2,515
	<u>12,450</u>	<u>3,558</u>

7. OTHER GAINS AND LOSSES

	For the six months ended 30 June	
	2022	2021
	<i>RMB'000</i>	<i>RMB'000</i>
	(Unaudited)	(Unaudited)
Net foreign exchange losses	(2,862)	(4,646)
Others	–	(73)
	<u>(2,862)</u>	<u>(4,719)</u>

8. FINANCE COSTS

	For the six months ended 30 June	
	2022	2021
	<i>RMB'000</i>	<i>RMB'000</i>
	(Unaudited)	(Unaudited)
Interest on bank and other borrowings	1,674	–
Interest on lease liabilities	1,430	1,267
	<u>3,104</u>	<u>1,267</u>

9. LOSS BEFORE TAX

Loss before tax for the period has been arrived at after charging/(crediting):

	For the six months ended 30 June	
	2022	2021
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Depreciation for plant and equipment	20,979	14,085
Depreciation for right-of-use assets	4,565	4,569
Loss on disposal of plant and equipment	–	73
Government grants and subsidies related to income	(12,206)	(2,515)
Staff cost (including directors' emoluments):		
– Independent non-executive directors' fee	151	151
– Salaries and other benefits	43,648	33,505
– Pension scheme contributions	4,569	3,065
– Share-based payment expenses	5,956	6,570
– Consultation fee	266	336
	<u>54,590</u>	<u>43,627</u>
Auditors' remuneration	900	700
Short-term lease payment	216	83
Expense incurred in intellectual property transfer agreement on CMAB807	–	66,038
Cost of intellectual property transfer agreement on CMAB806	–	16,769
Cost of service provided	11,028	–
Cost of inventories recognised as expense (included in research and development expense)	<u>9,364</u>	<u>12,432</u>

10. INCOME TAX

The Company was incorporated in the Cayman Islands and is exempted from income tax.

No Hong Kong profits tax was provided for as there was no estimated assessable profit of the Group's Hong Kong subsidiary that was subject to Hong Kong profits tax during the periods presented in the interim condensed consolidated financial information.

No PRC Enterprise Income tax was provided for as there was no estimated assessable profit of the Group's PRC subsidiaries during the periods presented in the interim condensed consolidated financial information.

Deferred taxation had not been recognised on the unused tax losses and deductible temporary differences since it is not probable that the taxable profits will be available against which the tax losses and deductible temporary differences can be utilised in the foreseeable future.

11. DIVIDENDS

No dividend was paid or proposed for ordinary shareholders of the Company during the six months ended 30 June 2022, nor has any dividend been proposed since the end of the reporting period (during the six months ended 30 June 2021: Nil).

12. LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE COMPANY

The calculation of the basic and diluted loss per share is based on the following data:

	For the six months ended 30 June 2022 RMB'000 (Unaudited)	2021 RMB'000 (Unaudited)
Loss attributable to ordinary equity holders of the Company for the purpose of calculating basic and diluted loss per share	<u>(116,809)</u>	<u>(145,161)</u>
	For the six months ended 30 June 2022 '000 (Unaudited)	2021 '000 (Unaudited)
Weighted average number of ordinary shares for the purpose of calculating basic and diluted loss per share	<u>4,124,080</u>	<u>4,124,080</u>

The calculation of diluted loss per share for the six months ended 30 June 2022 and 2021 did not assume the exercise of the pre-IPO share options since its inclusion would be anti-dilutive.

13. PLANT AND EQUIPMENT

During the six months ended 30 June 2022, the Group acquired assets with a cost of RMB133,572,000 (unaudited) including RMB132,570,000 (unaudited) of construction in process (for the six months ended 30 June 2021: RMB15,287,000 (unaudited) including RMB13,696,000 (unaudited) of construction in process).

During the six months ended 30 June 2022, no grants related to assets were deducted from the carrying amount of the assets (for the six months ended 30 June 2021: RMB33,109,000 (unaudited)).

14. OTHER NON-CURRENT ASSETS

	30 June 2022 RMB'000 (Unaudited)	31 December 2021 RMB'000 (Audited)
Prepayment for acquisition of plant and equipment (<i>note a</i>)	33,816	78,853
Deposit for construction of production facilities	3,000	3,000
VAT recoverable (<i>note b</i>)	<u>7,473</u>	<u>8,821</u>
	<u>44,289</u>	<u>90,674</u>

Notes:

- a. Prepayment for acquisition of plant and equipment is mainly related to the new production facilities on the parcel of industrial land of approximately 100,746 square meters in Taizhou Hi-tech Zone.
- b. VAT recoverable is presented in prepayments and other receivables and other non-current assets based on the management's estimation of the amount of VAT recoverable to be utilised within one year.

15. TRADE RECEIVABLES

	30 June 2022 RMB'000 (Unaudited)	31 December 2021 RMB'000 (Audited)
Trade receivables from third parties	3,850	793
Impairment	—	—
	<u>3,850</u>	<u>793</u>

An ageing analysis of the trade receivables as at the end of the reporting period, based on the invoice date and net of loss allowance, is as follows:

	30 June 2022 RMB'000 (Unaudited)	31 December 2021 RMB'000 (Audited)
Within 6 months	3,814	793
6 months to 1 year	36	—
	<u>3,850</u>	<u>793</u>

16. PREPAYMENTS AND OTHER RECEIVABLES

	30 June 2022 RMB'000 (Unaudited)	31 December 2021 RMB'000 (Audited)
Other receivables	1,915	2,435
Prepayments for research and development services	13,500	13,112
Other deposits and prepayments	5,325	4,261
VAT recoverable (<i>note</i>)	29,543	39,038
	<u>50,283</u>	<u>58,846</u>

Note: VAT recoverable is presented in prepayments and other receivables and other non-current assets based on the management's estimation of the amount of VAT recoverable to be utilised within one year.

17. TRADE AND OTHER PAYABLES

	30 June 2022 RMB'000 (Unaudited)	31 December 2021 RMB'000 (Audited)
Trade payables	28,874	12,860
Accrued expenses for research and development services	43,456	41,643
Other payables for purchases of plant and equipment	43,909	53,433
Salary and bonus payables	10,851	16,256
Other taxes payable	883	1,203
Accrued listing expenses and issue costs	10,601	10,103
Interest payable	35	–
Other payables	4,763	4,329
	<u>143,372</u>	<u>139,827</u>

Payment terms with suppliers are mainly on credit with 60 days from the time when the goods and/or services are received from the suppliers. The aging analysis of the trade payables presented based on the receipt of goods/services by the Group at the end of the reporting period is as follows:

	30 June 2022 RMB'000 (Unaudited)	31 December 2021 RMB'000 (Audited)
Within 60 days	22,256	11,315
Over 60 days but within 1 year	6,618	1,545
	<u>28,874</u>	<u>12,860</u>

18. INTEREST-BEARING BANK AND OTHER BORROWINGS

	30 June 2022			31 December 2021		
	Effective interest rate (%)	Maturity	Amount <i>RMB'000</i> (Unaudited)	Effective interest rate (%)	Maturity	Amount <i>RMB'000</i> (Audited)
Non-current:						
Other loans						
– unsecured	6.0%	2024	<u>51,475</u>	–	–	<u>–</u>
Bank loans	One-year loan prime rate					
– secured (note)	(“LPR”) +50 bps	2024	<u>29,650</u>	–	–	<u>–</u>
			<u><u>81,125</u></u>			<u><u>–</u></u>
				30 June 2022	31 December 2021	
				<i>RMB'000</i> (Unaudited)	<i>RMB'000</i>	(Audited)
Analysed into:						
Bank loans repayable:						
In the second year				<u>29,650</u>		<u>–</u>
Other loans repayable:						
In the third year				<u>51,475</u>		<u>–</u>
				<u><u>81,125</u></u>		<u><u>–</u></u>

Note: At 30 June 2022, the 100,746-square-meter land in Taizhou Hi-tech Zone with a carrying amount of approximately RMB35,474,000 and the 50,835-square-meter building with a carrying amount of approximately RMB117,918,000 were pledged to secure the bank borrowings of the Group.

The fair values of the non-current portion of interest-bearing bank and other borrowings have been calculated by discounting the expected future cash flows using rates currently available for instruments with similar terms, credit risk and remaining maturities. The differences between the carrying amounts and fair values of the non-current portion of interest-bearing bank and other borrowings were assessed to be insignificant. The changes in fair value as a result of the Group's own non-performance risk for interest-bearing bank and other borrowings as at 30 June 2022 were assessed to be insignificant.

19. SHARE-BASED PAYMENT TRANSACTIONS

Equity-settled share option scheme of the Company

The Company's Pre-IPO Share Option Scheme (the “Scheme”) were adopted pursuant to a resolution passed on 10 August 2018 for the primary purpose of providing incentives to directors of the Company and eligible employees of the Group. Under the Scheme, 1,875,000 options were granted on 18 August 2018 to directors of the Company and eligible employees of the Group to subscribe for shares in the Company, which will expire on 17 August 2028.

The Scheme has a service condition that shall vest over an 8-year period, with 20%, 20%, 20%, 20% and 20% of the total number of the options granted to be vested on the fourth, fifth, sixth, seventh and eighth anniversary of the listing date, respectively.

The exercise price in relation to each option granted shall be the final offer price per share at which the shares are to be acquired by the investors pursuant to the Hong Kong Public Offering and the International Offering, which shall not be less than the par value of the shares, provided that the exercise price shall be adjusted in the event of any capitalization issue, rights issue, open offer, sub-division, consolidation of shares, or reduction of capital of the Company.

On 8 April 2019, a shareholders' resolution about capitalization issue was passed and after taking into account of the capitalization issue the number of share options were increased to 83,512,500.

Particulars and movements in the Scheme are as follows:

<u>Date of grant</u>	<u>Outstanding at 1 January 2022</u>	<u>Granted</u>	<u>Exercised</u>	<u>Forfeited</u>	<u>Outstanding at 30 June 2022</u> (Unaudited)
18 August 2018	78,376,000	–	–	775,000	77,601,000

The Group recognised the total expense of RMB5,956,000 (unaudited) for the six months ended 30 June 2022 in relation to share options granted by the Company (for the six months ended 30 June 2021: RMB6,570,000 (unaudited)).

The fair value of the options granted was determined using the Binomial pricing model at the grant date.

20. CAPITAL COMMITMENTS

The Group had capital commitments for equipment purchase and building construction under contracts as follows:

	30 June 2022 <i>RMB'000</i> (Unaudited)	31 December 2021 <i>RMB'000</i> (Audited)
Contracted but not provided (<i>note</i>)	<u>63,712</u>	<u>138,649</u>

Note: The capital commitments are mainly related to the new production facilities on the parcel of industrial land of approximately 100,746 square meters in Taizhou Hi-tech Zone.

21. RELATED PARTY TRANSACTIONS

(a) The Group had the following transactions with related parties during the period:

	For the six months ended 30 June	
	2022	2021
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Expense incurred on intellectual property acquisition agreement: Shanghai Biomabs Pharmaceuticals Co., Ltd. ("Biomabs") (note a)	<u> -</u>	<u> 66,038</u>
Expenses incurred in clinical business and CMAB807 paid by a related party on behalf of the Group Biomabs	<u> 1,796</u>	<u> 3,124</u>
Repayments to a related party regarding to the expenses incurred in clinical business and CMAB807 paid by a related party on behalf of the Group: Biomabs	<u> 2,222</u>	<u> 383</u>
Interest on lease liabilities to a related party: Biomabs	<u> 385</u>	<u> 108</u>

Note:

Biomabs is ultimately controlled by a close family member of the controlling shareholder. In March 2021, the Group entered into an agreement with Biomabs in relation to the acquisition of the intellectual property in connection with CMAB807 from Biomabs at a consideration of RMB66,038,000 (excluding value added tax). Till 30 June 2022, the outstanding payable balance was accrued to RMB47,170,000 (unaudited). For further details regarding the acquisition of CMAB807, please refer to the announcement of the Company dated 1 March 2021, and the circular dated 13 April 2021 published on the websites of the Stock Exchange and the Company.

(b) Outstanding balances with related parties:

	30 June 2022 RMB'000 (Unaudited)	31 December 2021 RMB'000 (Audited)
Rental deposit to a related party: Biomabs	<u>411</u>	<u>411</u>
Amounts due from a related party: Prepayments – trade nature Biomabs	<u>8,849</u>	<u>8,849</u>
Prepayments – non-trade nature Biomabs	<u>603</u>	<u>603</u>
	<u>9,452</u>	<u>9,452</u>
Amounts due to a related party: Trade payables Biomabs	<u>47,231</u>	<u>47,225</u>
Non-trade payables Biomabs	<u>313</u>	<u>739</u>
	<u>47,544</u>	<u>47,964</u>
Lease liabilities payable to Biomabs: Within one year	<u>6,219</u>	4,199
Over one year	<u>6,469</u>	<u>8,481</u>
	<u>12,688</u>	<u>12,680</u>

Non-trade payables to Biomabs are unsecured, non-interest-bearing and repayable on demand.

Payment terms with suppliers are mainly on credit with 60 days from the time when the goods and/or services are received from the suppliers. The ageing analysis of the trade payables presented based on the receipt of goods/ services by the Group at the end of the reporting period is as follows:

	30 June 2022 RMB'000 (Unaudited)	31 December 2021 RMB'000 (Audited)
Within 60 days	21	55
Over 60 days but within 1 year	40	47,170
Over 1 year	<u>47,170</u>	<u>–</u>
	<u>47,231</u>	<u>47,225</u>

Trade payables to Biomabs are unsecured and non-interest-bearing.

(c) Compensation of key management personnel of the Group

	For the six months ended 30 June	
	2022 RMB'000 (Unaudited)	2021 RMB'000 (Unaudited)
Salaries and other benefits	2,276	2,538
Pension scheme contributions	149	134
Directors' fee	151	151
Share-based compensation	2,922	2,948
Consultation fee	<u>266</u>	<u>336</u>
	<u>5,764</u>	<u>6,107</u>

22. APPROVAL OF THE INTERIM FINANCIAL STATEMENTS

The interim financial statements were approved and authorised for issue by the board of directors on 26 August 2022.

OTHER INFORMATION

Interim Dividend

The Board does not recommend the payment of an interim dividend for the six months ended June 30, 2022.

Use of Net Proceeds from Listing

With the Shares of the Company listed on the Stock Exchange on May 31, 2019, the net proceeds from the Global Offering were approximately HK\$1,144.5 million (equivalent to approximately RMB1,005.1 million). As of June 30, 2022, the Company used a total of approximately RMB960.1 million of the proceeds, including approximately RMB180.9 million for research and development of our Core Products, approximately RMB489.9 million for production scale-up and construction of new production facilities in Taizhou, PRC, approximately RMB194.5 million for research and development of our other candidate products, approximately RMB74.8 million for working capital and general purpose and approximately RMB20.0 million for acquisition of CMAB807 license. Saved as disclosed below, the Company intends to apply such net proceeds in accordance with the purposes as set out in the Prospectus and the announcement published by the Company on March 1, 2021.

The table below sets out the planned applications of the net proceeds of the Global Offering and actual usage up to June 30, 2022: ⁽¹⁾⁽²⁾

Use of proceeds	Allocation of the net proceeds (RMB million)	Utilized amount (as of June 30, 2022) (RMB million)	Unutilized amount (as of June 30, 2022) (RMB million)	Expected timeline for fully utilizing the unutilized amount
For R&D of our Core Products	180.9	180.9	0.0	
For production scale-up and construction of new production facilities in Taizhou, PRC	497.2	489.9	7.3	By December 31, 2022
For R&D of our other product candidates	194.5	194.5	0.0	
For working capital and other general corporate purposes	74.8	74.8	0.0	-
For acquisition of CMAB807 License ⁽³⁾	20.0	20.0	0.0	-
Total	<u>967.4</u>	<u>960.1</u>	<u>7.3</u>	

Note:

- (1) The net proceeds of the Global Offering were received in Hong Kong dollar and translated to Renminbi for application planning.
- (2) The expected timeline for utilization of the unutilized proceeds disclosed above is based on the best estimation from the Board with latest information as of the date of this announcement.
- (3) On March 1, 2021, the Board resolved to allocate approximately RMB20 million of the net proceeds originally allocated for working capital and other general corporate purposes to finance part of the consideration payable for the acquisition of CMAB807. For further details regarding the acquisition of CMAB807 and the change in use of proceeds, please refer to the announcement and circular of the Company dated March 1, 2021 and April 13, 2021, respectively, published on the websites of the Stock Exchange and the Company.

Significant Investments, Material Acquisitions and Disposals

Save as disclosed in this announcement, as at the date of this announcement, there were no significant investments held by the Group or future plans regarding significant investment or capital assets. For the six months ended June 30, 2022, we did not have material acquisitions or disposals of subsidiaries, associates and joint ventures.

Employee and Remuneration Policy

As of June 30, 2022, we had a total of 389 employees, of which 74 are located in Shanghai and 315 are located in Taizhou. The table below sets forth a breakdown of our employees by function:

Function	Number of Employees
Business units	71
R&D personnel ⁽¹⁾	247
Administration	28
Management	43
	<hr/>
Total	389
	<hr/> <hr/>

Notes:

- (1) The number of R&D personnel here excludes 24 R&D team members who have been included in our management.

Our success depends on our ability to attract, recruit and retain qualified employees. We provide our employees with opportunities to work on cutting-edge biologics projects with world-class scientists. We aim to attract qualified employees with overseas educational backgrounds and relevant experience gained from global pharmaceutical or biotechnology companies. As of June 30, 2022, Dr. Li Jing and Dr. Wang Hao of our scientists held a Ph.D. degree or equivalent in fields that are highly relevant to our business. In addition, as of the same date, 164 out of our 271 R&D personnel (including those who are our management) held a bachelor's degree or above.

Our employment agreements typically cover matters such as wages, benefits and grounds for termination. The remuneration package of our employees generally includes salary and bonus elements. In general, we determine the remuneration package based on the qualifications, position and performance of our employees. We also make contributions to the social insurance fund, including basic pension insurance, medical insurance, unemployment insurance, childbirth insurance, work-related injury insurance funds, and housing reserve fund.

We have established a labor union at Taizhou that represents employees with respect to the promulgation of bylaws and internal protocols. As of June 30, 2022, all of our employees at Taizhou were members of the labor union. We believe that we maintain a good working relationship with our employees. We had not experienced any material difficulty in recruiting employees for our operations during the Reporting Period and up to the date of this announcement.

COMPLIANCE WITH THE CORPORATE GOVERNANCE CODE

The Group is committed to maintaining high standard of corporate governance to safeguard the interests of the Shareholders, enhance corporate value, formulate its business strategies and policies, and enhance its transparency and accountability.

The Company's corporate governance practices are based on the principles and code provisions as set out in the CG Code contained in Appendix 14 to the Listing Rules and the Company has adopted the CG code as its own code of corporate governance. The Board is of the view that the Company has complied with the applicable code provisions as set out in the CG Code for the six months ended June 30, 2022 and up to the date of this announcement. The Board will periodically review and enhance its corporate governance practices to ensure that the Company continues to meet the requirements of the CG Code.

COMPLIANCE WITH THE MODEL CODE FOR SECURITIES TRANSACTIONS

The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix 10 to the Listing Rules as the guidelines for the Directors' dealings in the securities of the Company.

Specific enquiry has been made to each Director and all Directors have confirmed that they have complied with the applicable standards set out in the Model Code for the six months ended June 30, 2022 and up to the date of this announcement.

PURCHASE, SALE OR REDEMPTION OF THE COMPANY’S LISTED SECURITIES

Neither the Company nor any of its subsidiaries purchased, sold or redeemed any of the Company’s listed securities on the Stock Exchange during the Reporting Period.

MATERIAL LITIGATION

The Company was not involved in any material litigation or arbitration during the Reporting Period. The Directors are also not aware of any material litigation or claims that are pending or threatened against the Group during the Reporting Period.

AUDIT COMMITTEE AND REVIEW OF FINANCIAL REPORT

The independent auditors of the Company, namely Ernst & Young, have carried out a review of the interim financial information in accordance with the Hong Kong Standard on Review Engagement 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Hong Kong Institute of Certified Public Accountants.

The Audit Committee has examined the efficiency of our risk management and internal control system and is convinced that our internal control system is sufficient to identify, manage and reduce various risks arising from our business activities. The Audit Committee consists of two independent non-executive Directors, being Mr. Leung, Louis Ho Ming and Mr. Guo Liangzhong, and one non-executive Director, being Mr. Jiao Shuge. Mr. Leung, Louis Ho Ming serves as chairman of the Audit Committee.

The Audit Committee has reviewed the interim consolidated financial statements of the Group for the six months ended June 30, 2022. The Audit Committee has also discussed matters with respect to the accounting principles and policies adopted by the Company and internal control with members of senior management and the external auditors of the Company, Ernst & Young.

PUBLICATION OF INTERIM REPORT

This announcement is published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.mabpharm.cn).

The interim report for the six months ended June 30, 2022, containing all the information as required under Appendix 16 of the Listing Rules, will be despatched to the Shareholders and published on the websites of the Stock Exchange and the Company in due course.

SIGNIFICANT EVENTS AFTER THE REPORTING PERIOD

There was no significant event subject to disclosure from June 30, 2022 and up to the date of this announcement.

APPRECIATION

On behalf of the Board, I wish to express my sincere gratitude to our Shareholders and business partners for their continued support, and to our employees for their dedication and hard work.

DEFINITIONS

In this announcement, the following expressions have the meanings set out below unless the context requires otherwise:

“Audit Committee”	the audit committee of the Board
“Biomabs”	Shanghai Biomabs Pharmaceuticals Co., Ltd. (上海百邁博製藥有限公司), a limited liability company incorporated in the PRC on October 16, 2009 and a direct wholly-owned subsidiary of Sinomab as of the date of this announcement
“Board” or “Board of Directors”	the board of Directors of the Company
“CDMO”	Contract Development Manufacture Organization
“CG Code”	the Corporate Governance Code as set out in Appendix 14 to the Listing Rules
“cGMP”	current Good Manufacturing Practice
“Company”	Mabpharm Limited (迈博药业有限公司), an exempted company incorporated in the Cayman Islands with limited liability on June 1, 2018 and whose Shares are listed on the Stock Exchange
“connected person(s)”	has the meaning ascribed to it under the Listing Rules
“Core Product(s)”	has the meaning ascribed to it in Chapter 18A of the Listing Rules; for the purpose of this announcement, our Core Products include CMAB007, CMAB009 and CMAB008
“Director(s)”	the director(s) of our Company
“Global Offering”	has the meaning ascribed to it under the Prospectus
“GMP”	Good Manufacturing Practice of Medical Products
“Group”, “our Group”, “the Group”, “we”, “us”, or “our”	the Company and its subsidiaries from time to time

“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Hong Kong dollars” or “HK dollar” or “HK\$”	Hong Kong dollars, the lawful currency of Hong Kong
“IBD”	inflammatory bowel disease
“IPO”	initial public offering
“Listing”	the listing of Shares on the Main Board of the Stock Exchange on May 31, 2019
“Listing Date”	May 31, 2019, being the date on which the Shares were listed on the Main Board of the Stock Exchange
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange
“Main Board”	the Main Board of the Stock Exchange
“mCRC”	metastatic colorectal cancer
“Model Code”	the Model Code for Securities Transactions by Directors of Listed Issuers contained in Appendix 10 to the Listing Rules
“NDA”	new drug application
“PRC”	the People’s Republic of China, excluding, for the purposes of this announcement, Hong Kong Special Administrative Region, the Macau Special Administrative Region and Taiwan
“Prospectus”	the prospectus issued by the Company on May 20, 2019 in connection with the Hong Kong public offering of the Shares
“Reporting Period”	six months from January 1, 2022 to June 30, 2022
“RMB”	Renminbi, the lawful currency of the PRC
“Shares”	ordinary share(s) in the capital of the Company with nominal value of US\$0.0001 each
“Shareholder(s)”	holder(s) of Share(s)

“Sinomab” Sinomab Limited (formerly known as Mabtech Limited), a limited liability company incorporated in the Cayman Islands on September 4, 2014, and a company which the controlling shareholder of the Company and its associate in aggregate indirectly controls 66.67% voting rights as of the date of this announcement

“Stock Exchange” The Stock Exchange of Hong Kong Limited

By Order of the Board
Mabpharm Limited
Jiao Shuge
Chairman

Hong Kong, August 26, 2022

As at the date of this announcement, the Board of Directors comprises Dr. Wang Hao, Mr. Tao Jing, Mr. Li Yunfeng and Dr. Li Jing as executive Directors; Mr. Jiao Shuge and Mr. Guo Jianjun as non-executive Directors; and Mr. Guo Liangzhong, Dr. Zhang Yanyun and Mr. Leung, Louis Ho Ming as independent non-executive Directors.